PipelineReview.com17h
Phanes Therapeutics Announces First Patient Dosed in Clinical Study of Peluntamig (PT217) in Combination with Chemotherapy
SAN DIEGO, CA, USA I February 19, 2025 I Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and ...
A lingering question at Coinbase: Who really owns the customers’ crypto?
An odd thing happened when Coinbase reported its quarterly financial results last week. The bulk of its assets and ...
JENNI MURRAY: My biggest regret in life? Ignoring the letter offering a cancer scan
My surgeon gently chided me during my consultation. Had I had the mammogram when I was invited, a lumpectomy might have ...
Jannik Sinner doping ban: WADA defends settlement, says it has entered ‘70-odd such agreements’ in last four years
Sinner failed two dope tests, testing positive for banned anabolic steroid clostebol, in March last year but was found “to ...
Cure Today2d
The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma
The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or ...